Infectious Vaccines Partnering Terms and Agreements
LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Infectious Vaccines Partnering Terms and Agreements
The Infectious Vaccines Partnering Terms and Agreements provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies.
The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2009, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading infectious vaccines deals since 2009. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the big biotech companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since January 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in infectious vaccines partnering and dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectious vaccines technologies and products.
Report scope
Infectious Vaccines Partnering Agreements is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.
Infectious Vaccines Partnering Agreements includes:
Trends in infectious vaccines dealmaking in the biopharma industry since 2009
Analysis of infectious vaccines deal structure
Access to headline, upfront, milestone and royalty data
Access to over 500 infectious vaccines deal records
The leading infectious vaccines deals by value since 2009
Includes adjuvant deals and alliances since 2009
In Infectious Vaccines Partnering Agreements, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific infectious therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Infectious Vaccines Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:
• In-depth understanding of infectious vaccines deal trends since 2009
• Access infectious vaccines deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between infectious vaccines partner companies
• Comprehensive access to over 500 links to actual infectious vaccines deals entered into by the world's biopharma companies
• Indepth review of infectious vaccines deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner infectious vaccines opportunities
• Uncover companies actively partnering infectious vaccines opportunities
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in infectious vaccines dealmaking
2.1. Introduction2.2. Infectious vaccines partnering over the years2.3. Big pharma infectious vaccines dealmaking activity2.4. Big biotech infectious vaccines dealmaking activity2.5. Most active in infectious vaccines partnering2.6. Infectious Vaccines partnering by deal type2.7. Infectious vaccines partnering by stage of development2.8. Infectious vaccines partnering by infectives indication2.9. Infectious vaccines partnering by vaccine and adjuvant indication2.10. Disclosed deal terms for infectious vaccines partnering2.10.1 Infectious vaccines partnering headline values2.10.2 Infectious Vaccines deal upfront payments2.10.3 Infectious Vaccines deal milestone payments2.10.4 Infectious Vaccines royalty rates2.11. The anatomy of Infectious Vaccines partnering2.11. The anatomy of an infectious vaccines deal2.11.a. Case study 1: Gilead Sciences, GlobeImmune- Oct 24 20112.11.b. Case study 2: Astellas, Vical: July 14, 2011
Chapter 3 – Leading infectious vaccines deals
3.1. Introduction3.2. Top infectious vaccines deals by value
Chapter 4 – Big pharma infectious vaccines deals
4.1. Introduction4.2. How to use big pharma partnering deals4.3. Big pharma infectious vaccines partnering company profilesAbbottAstellasDaiichi SankyoGilead SciencesGlaxoSmithKlineJohnson & JohnsonMerck & CoNovartisPfizerRocheSanofiTakeda
Chapter 5 – Big biotech infectious vaccines deals
5.1. Introduction5.2. How to use big biotech partnering deals5.3. Big biotech Infectious Vaccines partnering company profilesBavarian NordicCangeneEmergent BioSolutions
Chapter 6 – Infectious Vaccines dealmaking directory
6.1. Introduction6.2. Company A-Z6.3. By deal typeAsset purchaseAssignmentBigpharma outlicensingCo-developmentCollaborative R&DCo-marketContract serviceCo-promotionCRADACross-licensingDevelopmentDistributionEquity purchaseEvaluationGrantJoint ventureLicensingManufacturingMarketingMaterial transferOptionPromotionResearchSettlementSpin outSub-licenseSupplyTechnology transferTerminationWarranty6.4. By stage of developmentDiscoveryPreclinicalPhase IPhase IIPhase IIIRegulatoryMarketedFormulation6.5. By infectives therapy areaInfectives6.5. By vaccine and adjuvant technology areaVaccinesAdjuvant
Chapter 7 –Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmakingAppendices
Appendix 1 – Deal type definitionsAbout Wildwood VenturesCurrent PartneringCurrent AgreementsRecent report titles from CurrentPartneringOrder Form – Therapy Reports
Table of figures
Figure 1: Infectious vaccines partnering since 2009Figure 2: Big pharma – top 50 – Infectious Vaccines deals 2009-2014Figure 3: Big pharma infectious vaccines deal frequency – 2009 to 2014Figure 4: Big biotech – top 50 – Infectious Vaccines deals 2009 to 2014Figure 5: Big biotech infectious vaccines deal frequency – 2009 to 2014Figure 6: Active infectious vaccines dealmaking activity– 2009 to 2014Figure 7: Infectious vaccines partnering by deal type since 2009Figure 8: Infectious vaccines partnering by stage of development since 2009Figure 9: Infectious vaccines partnering by infectives target since 2009Figure 10: Infectious vaccines partnering by specific technology target since 2009Figure 11: Infectious Vaccines deals with a headline value – by stage of developmentFigure 12: Infectious Vaccines deal headline value distribution, US$million – discovery stageFigure 13: Infectious Vaccines deal headline value distribution, US$million – preclinical stageFigure 14: Infectious Vaccines deal headline value distribution, US$million – phase I stageFigure 15: Infectious Vaccines deal headline value distribution, US$million – phase II stageFigure 16: Infectious Vaccines deal headline value distribution, US$million – phase III stageFigure 17: Infectious Vaccines deal headline value distribution, US$million – marketed stageFigure 18: Infectious vaccines deal headline value – median value by stage of developmentFigure 19: Infectious Vaccines deals with upfront payment values – by stage of developmentFigure 20: Infectious Vaccines deal upfront payment value distribution, US$million – discovery stageFigure 21: Infectious Vaccines deal upfront payment value distribution, US$million – preclinical stageFigure 22: Infectious Vaccines deal upfront payment value distribution, US$million – phase I stageFigure 23: Infectious Vaccines deal upfront payment value distribution, US$million – phase II stageFigure 24: Infectious Vaccines deal upfront payment value distribution, US$million – phase III stageFigure 25: Infectious Vaccines deal upfront payment value distribution, US$million – marketed stageFigure 26: Infectious vaccines deal upfront payment value – median value by stage of developmentFigure 27: Infectious Vaccines deals with milestone payment – by stage of developmentFigure 28: Infectious Vaccines deal milestone payment value distribution, US$million – discovery stageFigure 29: Infectious Vaccines deal milestone payment value distribution, US$million – preclinical stageFigure 30: Infectious Vaccines deal milestone payment value distribution, US$million – phase I stageFigure 31: Infectious Vaccines deal milestone payment value distribution, US$million – phase II stageFigure 32: Infectious Vaccines deal milestone payment value distribution, US$million – phase III stageFigure 33: Infectious Vaccines deal milestone payment value distribution, US$million – marketed stageFigure 34: Infectious Vaccines deals with royalty rates-by stage of developmentFigure 35: Infectious Vaccines deal royalty rate payment value distribution, US$million – discovery stageFigure 36: Infectious Vaccines deal royalty rate payment value distribution, US$million – preclinical stageFigure 37: Infectious Vaccines deal royalty rate payment value distribution, US$million – phase I stageFigure 38: Infectious Vaccines deal royalty rate payment value distribution, US$million – phase II stageFigure 39: Infectious Vaccines deal royalty rate payment value distribution, US$million – phase III stageFigure 40: Infectious Vaccines deal royalty rate payment value distribution, US$million – marketed stageFigure 41: Infectious Vaccines deal royalty rate payment value – median value by stage of developmentFigure 42: Components of the typical Infectious Vaccines deal structureFigure 43: Top infectious vaccines deals by value since 2009Figure 44: Online partnering resourcesFigure 45: Forthcoming partnering eventsFigure 46: Deal type definitions 6.3. By deal typeAsset purchaseAssignmentBigpharma outlicensingCo-developmentCollaborative R&DCo-marketContract serviceCo-promotionCRADACross-licensingDevelopmentDistributionEquity purchaseEvaluationGrantJoint ventureLicensingLitigationManufacturingManufacturing - OEMMarketingMaterial transferOptionPromotionResearchSettlementSpin outSub-licenseSupplyTechnology transferTerminationWarranty6.4. By stage of developmentDiscoveryFormulationMarketedPhase IPhase IIPhase IIIPreclinicalRegulatory6.5. By infectives therapy area6.5. By vaccine and adjuvant technology areaVaccinesAdjuvant
Chapter 7 –Partnering resource center
7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitionsAbout Wildwood VenturesCurrent PartneringCurrent AgreementsRecent report titles from CurrentPartneringOrder Form – Therapy Reports
Table of figures
Figure 1: Infectious Vaccines partnering since 2007
Figure 2: Bigpharma – top 50 – Infectious Vaccines deals 2007 to 2013
Figure 3: Big pharma Infectious Vaccines deal frequency – 2007 to 2013
Figure 4: Big biotech – top 50 – Infectious Vaccines deals 2007 to 2013
Figure 5: Big biotech Infectious Vaccines deal frequency – 2007 to 2013
Figure 6: Active cancer vaccine dealmaking activity– 2007 to 2013
Figure 7: Infectious Vaccines partnering by deal type since 2007
Figure 8: Infectious Vaccines partnering by stage of development since 2007
Figure 9: Infectious Vaccines partnering by infectives target since 2007
Figure 10: Infectious Vaccines partnering by specific technology target since 2007
Figure 11: Infectious Vaccines deals with a headline value – by stage of development
Figure 12: Infectious Vaccines deal headline value distribution, US$million – discovery stage
Figure 13: Infectious Vaccines deal deal headline value distribution, US$million – preclinical stage
Figure 14: Infectious Vaccines deal deal headline value distribution, US$million – phase I stage
Figure 15: Infectious Vaccines deal headline value distribution, US$million – phase II stage
Figure 16: Infectious Vaccines deal deal headline value distribution, US$million – phase III stage
Figure 17: Infectious Vaccines deal deal headline value distribution, US$million – marketed stage
Figure 18: Infectious Vaccines deal headline value – median value by stage of development
Figure 19: Infectious Vaccines deals with upfront payment values – by stage of development
Figure 20: Infectious Vaccines deal upfront payment value distribution, US$million – discovery stage
Figure 21: Infectious Vaccines deal upfront payment value distribution, US$million – preclinical stage
Figure 22: Infectious Vaccines deal upfront payment value distribution, US$million – phase I stage
Figure 23: Infectious Vaccines deal upfront payment value distribution, US$million – phase II stage
Figure 24: Infectious Vaccines deal upfront payment value distribution, US$million – phase III stage
Figure 25: Infectious Vaccines deal upfront payment value distribution, US$million – marketed stage
Figure 26: Cancer vaccine deal upfront payment value – median value by stage of development
Figure 27: Infectious Vaccines deals with milestone payment – by stage of development
Figure 28: Infectious Vaccines deal milestone payment value distribution, US$million – discovery stage
Figure 29: Infectious Vaccines deal milestone payment value distribution, US$million – preclinical stage
Figure 30: Infectious Vaccines deal milestone payment value distribution, US$million – phase I stage
Figure 31: Infectious Vaccines deal milestone payment value distribution, US$million – phase II stage
Figure 32: Infectious Vaccines deal milestone payment value distribution, US$million – phase III stage
Figure 33: Infectious Vaccines deal milestone payment value distribution, US$million – marketed stage
Figure 34: Infectious Vaccines deals with royalty rates-by stage of development
Figure 35: Infectious Vaccines deal royalty rate payment value distribution, US$million – discovery stage
Figure 36: Infectious Vaccines deal royalty rate payment value distribution, US$million – preclinical stage
Figure 37: Infectious Vaccines deal royalty rate payment value distribution, US$million – phase I stage
Figure 38: Infectious Vaccines deal royalty rate payment value distribution, US$million – phase II stage
Figure 39: Infectious Vaccines deal royalty rate payment value distribution, US$million – phase III stage
Figure 40: Infectious Vaccines deal royalty rate payment value distribution, US$million – marketed stage
Figure 41: Infectious Vaccines deal royalty rate payment value – median value by stage of development
Figure 42: Components of the typical Infectious Vaccines deal structure
Figure 43: Top Infectious Vaccines deals by value since 2007
Figure 44: Online partnering resources
Figure 45: Forthcoming partnering events
Figure 46: Deal type definitions
Read the full report:
Infectious Vaccines Partnering Terms and Agreements
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article